Company intelligence / Profile preview

BioHalo

Copenhagen, Denmarkbii.dk ↗

Ownership: Private
Development stage: Preclinical

Overview

BioHalo has developed an energy-efficient and eco-friendly technology using engineered bacteria to produce high-performance polymers as alternatives to PFAS ("forever chemicals"). Their biopolymers are designed to match the performance of conventional PFAS while minimizing environmental impact. The company is currently focused on scaling up production and commercializing its platform, having won innovation awards such as JEC World’s 2024 Startup Booster competition. No clinical results apply.

Industry: Non-Drug Biotech

Partnerships

Plug and Play JapanBioInnovation Institute Venture Lab Program

Beyond the preview

Go deeper on BioHalo.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioHalo.

Explore the full profile